Table 3 Treatment for acute exacerbation in patients with IPF and CPFE-UIP
Treatment | Patients with IPF (n = 41) | Patients with CPFE (n = 21) | p-value |
|---|---|---|---|
Number of patients using corticosteroids | 41 (100%) | 21 (100%) | – |
Number of patients of using immunosuppressants | 19 (46.3%) | 4 (19.0%) | 0.08 |
CY | 14 (34.1%) | 3 (14.3%) | |
CyA | 4 (9.7%) | 2 (9.5%) | |
TAC | 1 (2.4%) | 0 (0%) | |
Number of patients receiving respiratory care | 0.927 | ||
IPPV | 8 (19.5%) | 3 (14.3%) | |
NPPV | 13 (31.7%) | 7 (33.3%) | |
HFT | 3 (7.3%) | 1 (4.8%) | |
Only O2 | 17 (41.5%) | 10 (47.6%) | |
Duration of positive-pressure ventilation (days) | 9.5 (3.75–39.25) (n = 20) | 5(3.25–7.75) (n = 10) | 0.628 |
ICU stay (days) | 10 (4–17.) (n = 13) | 4.5 (3.25–8) (n = 6) | 0.122 |